Meeting
2016 Gastrointestinal Cancers Symposium
Frequency of HER2 mutations and amplification in GI malignancies and ability of pertuzumab to overcome neuregulin1 mediated drug resistance to a HER2 tyrosine kinase inhibitor in colon cancer.
Authors
Ron Bose
Washington University School of Medicine in St. Louis, St. Louis, MO
Ron Bose , Siraj Ali , Naveen Jain , Kyle Gowen , Andrea Bertotti , Elisa Murray , Jeffrey S. Ross , Mary Stanley Beattie , Herbert Hurwitz , John D. Hainsworth
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 630)
DOI
10.1200/jco.2016.34.4_suppl.630
Abstract #
630
Poster Bd #
G13
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2 targeted drugs: Results form the EUHER2 cohort study.
First Author: Julien Mazières
Poster
2015 ASCO Annual Meeting
Effect of somatic mutations in the four genes of the HER family on occurrence in HER2-positive breast cancer, cell proliferation rates, and resistance to HER2-targeted therapies in vitro.
First Author: Naomi Elster
Poster
2014 ASCO Annual Meeting
Preclinical activity of MCLA-128, an ADCC enhanced bispecific IgG1 antibody targeting the HER2:HER3 heterodimer.
First Author: Cecile Geuijen
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Identification of MAPK and mTOR pathway alterations in HER2-amplified colorectal cancer.
First Author: Svea Cheng